TV show: BIOVALIANCE at the heart of the biotherapy boom

Bourgogne-Franche-Comté region continues its efforts to become a key region for innovation in healthcare. At the Innovative Therapies Days event organized in Besançon by PMT, researchers, manufacturers, and institutional stakeholders reiterated the region’s proactive strategy in favor of biotherapies, medicines derived from living organisms that are expected to account for nearly 60% of tomorrow’s treatments.

In its latest issue of “Rendez-vous de l’innovation santé”, ON HEALTH traveled to Besançon for a special program on BIOVALIANCE, the regional initiative promoting biotherapies, with guests Philippe Dulieu, CEO of RD-Biotech, Claudine Vermot-Desroches, CEO of Abtx, and Yann Godet, coordinator of the INTHERAPI training program.

Watch the program here:

BIOVALIANCE, a regional brand

At the heart of this ecosystem, BIOVALIANCE plays a structuring role. This regional network brings together all the expertise necessary for the development of biotherapies: biologists, university teams, biotechnology companies, as well as players in diagnostics, imaging, and bioproduction. “The aim is to make the entire regional value chain visible and coherent,” emphasizes Philippe Dulieu, CEO of RD-Biotech. This is essential to accelerate the transition from innovation to industrialization.

Regional support also translates into significant investment in training and research. Dedicated master’s and doctoral programs, national initiatives such as France 2030, and pathways to entrepreneurship are helping to develop the skills of tomorrow. This is a strategic issue, as manufacturers warn of a shortage of qualified bioproduction professionals. By 2030, Bourgogne-Franche-Comté aims to establish itself as a recognized European player in biotherapies. This collective ambition is driven by BIOVALIANCE, in the service of innovation, employment, and, above all, patients.